Transcend Therapeutics, Inc.·Otsuka Pharmaceutical Co., Ltd. (through wholly owned subsidiary Otsuka America, Inc.)

Structure

Otsuka release 2026-03-27 (https://www.otsuka.co.jp/en/company/newsreleases/2026/20260327_2.html): 'Otsuka will pay USD 700 million to Transcend shareholders upon closing of the acquisition, and up to USD 525 million in additional contingent consideration based on future sales milestones related to assets in development, for a total potential consideration of USD $1.225 billion.' Otsuka release 2026-06-15: 'the acquisition of Transcend Therapeutics, Inc. (Transcend) by its wholly owned subsidiary, Otsuka America, Inc. (OAI), has been completed'; 'Otsuka paid USD 700 million to the shareholders of Transcend as consideration for the acquisition of all outstanding shares of the company. In addition, Otsuka may pay up to USD 525 million in additional contingent consideration based on future sales related to assets in development.' Wording differs between the releases: 'future sales milestones' (March) and 'future sales' (June). close_date is the completion release date; no separate closing date is given. Otsuka Pharmaceutical is not an SEC registrant and Transcend is private: no SEC filing exists. Japanese exchange disclosures (TDnet, EDINET) were not retrieved. Native USD, no FX. SOURCE SCOPE, recorded 2026-09-22: this row rests on two Otsuka English press releases and nothing else. TDnet, the Tokyo Stock Exchange timely-disclosure service, and EDINET, the FSA filing system, were NOT checked as of 2026-09-22, and Otsuka Holdings (TSE 4578) files its statutory disclosure there rather than with the SEC. That is why confidence stays reported and not verified: no primary registry or statutory filing has been read for this deal. Issue 15 says in print that the Japanese filings are unread; this row is what that sentence rests on.

Why it matters

Contingent consideration is keyed to sales, not to approval or rescheduling milestones. Otsuka describes TSND-201 as having 'no activity at 5-HT2A receptors (i.e., not hallucinogenic)'. The Phase 2 IMPACT-1 trial enrolled 65 patients 'across 16 sites in the U.S., the U.K., and Ireland' (release 2026-03-27). FDA Breakthrough Therapy designation July 2025; Commissioner's National Priority Voucher April 2026 (release 2026-06-15).

In the briefing

• 2026-09-22No. 15

  The CVR is an option, and Lilly holds it

  • DEALS
  • REGULATORY
  • TRIALS
  • LILLY
  • ATAIBECKLEY
  • COMPASS
  • ABBVIE
  • OTSUKA